NewsRx

Search our medical news database

Prostate Cancer

Antigen Construct, Cytokine Combo Treats and Prevents Male Malignancies

Published in Vaccine Weekly, December 26th, 2001

by Sonia Nichols, senior medical writer - University of Iowa researchers have developed recombinant therapies that can treat and prevent prostate cancer tumors in mice.

According to a contingent of investigators at the Iowa City, Iowa university, "Prostatic malignancies in 95% of patients continue to express PSA, making this antigen a good candidate for targeted immunotherapy." Because the cells in the prostrate are significant producers of PSA, they are key targets for directed therapies such as that developed by Bennett D. Elzey and others at University of Iowa.

The first portion of the therapy, an adenovirus construct, expresses recombinant...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook